Deferasirox
ТаблеткиAn oral chelator whose primary use is to reduce chronic iron overload in patients receiving long-term blood transfusions for conditions such as beta-thalassaemia and other chronic anaemias.
Important
Indications
The drug Deferasirox is intended for oral administration and is indicated for the prevention and treatment of:
- chronic post-transfusion iron overload in adults and children aged 2 years and older;
- chronic non-transfusion iron overload in patients with thalassaemia aged 10 years and older.
If there is no improvement or you (or your child) feel worsening, you should contact your doctor immediately.
Contraindications
Do not use Deferasirox:
- If you are allergic to deferasirox or any other components of the medicine (listed in section 6 of the leaflet insert);
- if you have a creatinine clearance (CK) <60 ml/min or a serum creatinine concentration 2 or more times the upper limit of the age-standardised range;
- if you have high-risk myelodysplastic syndrome or other haemoblastosis and non-haematological malignancies in which chelation therapy will be ineffective due to rapid disease progression;
- If you have severe liver function impairment (Child-Pugh class C);
- If you are pregnant or breastfeeding;
- if your child is less than 2 years old (no experience of use).
If you think any of these apply to you or your child, tell your doctor.
Usage
Always take the drug in full compliance with the recommendations of your doctor. If in doubt, consult your doctor. The recommended dose of Deferasirox for all patients is based on body weight. Your doctor will calculate the dose you need and tell you how many tablets you should take each day.
- 20 mg/kg body weight for patients with chronic post-transfusion iron overload;
- 10 mg/kg body weight for patients with thalassaemia and chronic non-transfusion iron overload.
Depending on your individual needs and response to treatment, your doctor may recommend a higher or lower starting dose and adjust the dose subsequently.
The maximum recommended daily dose is:
- 40 mg/kg body weight for patients with chronic post-transfusion iron overload;
- 20 mg/kg body weight for thalassaemic patients with chronic non-transfusion iron overload;
- 10 mg/kg body weight for patients with serum ferritin concentration <2000 µg/L without liver iron determination in chronic non-transfusion iron overload.
When switching from deferoxamine or deferasirox therapy in another dosage form to Deferasirox, dispersible tablets, a dose adjustment should be made, for this purpose consult your physician. Only the attending physician can select the correct dose of the drug Deferasirox.
Have questions? Contact Us
Drugs in the category Intensive therapy
Has contraindications. Needs specialist overview.